ObsEva boosted by positive Phase III data

9 December 2019

Swiss women’s health specialist ObsEva (Nasdaq: OBSV) has reported positive Phase III results from the PRIMROSE 2 trial of linzagolix, with shares in the company rising nearly a fifth in pre-market trading.

ObsEva is developing the candidate for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids.

The study met its primary efficacy endpoint, a reduction in HMB. The responder rate was 93.9% at the higher dose level and 56.7% at the lower dose level, compared to 29.4% in the placebo group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK